BridgeBio Pharma (BBIO) Liabilities and Shareholders Equity (2018 - 2026)

BridgeBio Pharma (BBIO) has 9 years of Liabilities and Shareholders Equity data on file, last reported at $1.4 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 55.5% year-over-year to $1.4 billion; the trailing twelve-month figure through Mar 2026 stood at $4.4 billion (up 34.51% YoY), and the FY2025 full-year result was $936.0 million, up 1.82% from the prior year.
• Liabilities and Shareholders Equity improved to $1.4 billion in Q1 2026, from $936.0 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.4 billion in Q1 2026 to a low of $503.7 million in Q2 2023.
• A 5-year average of $814.9 million and a median of $813.1 million in 2022 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity slumped 41.59% in 2023 and jumped 68.26% in 2024, its largest moves.
• Tracing BBIO's Liabilities and Shareholders Equity over 5 years: stood at $623.0 million in 2022, then dropped by 12.3% to $546.4 million in 2023, then jumped by 68.26% to $919.3 million in 2024, then increased by 1.82% to $936.0 million in 2025, then soared by 46.47% to $1.4 billion in 2026.
• Business Quant data shows BBIO's Liabilities and Shareholders Equity at $1.4 billion in Q1 2026, $936.0 million in Q4 2025, and $998.2 million in Q3 2025.